Sign in or create an account to add this stock to your watchlist.
About Avid Bioservices (NASDAQ:CDMO)
Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support. It also offers various process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. is based in Tustin, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.74
Price-To-Earnings
Trailing P/E Ratio-4.05
Forward P/E Ratio-5.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$57.63 million
Price / Sales3.43
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book2.83
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-28,150,000.00
Net Margins-46.62%
Return on Equity-57.49%
Return on Assets-28.83%
Miscellaneous
Employees323
Outstanding Shares55,550,000
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
How often does Avid Bioservices pay dividends? What is the dividend yield for Avid Bioservices?
Avid Bioservices declared a dividend on Wednesday, March 7th. Stockholders of record on Monday, March 19th will be given a dividend of $0.6563 per share on Monday, April 2nd. The ex-dividend date of this dividend is Friday, March 16th. View Avid Bioservices' Dividend History.
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices (NASDAQ:CDMO) posted its quarterly earnings data on Monday, March, 12th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.09. The biopharmaceutical company had revenue of $6.82 million for the quarter, compared to analyst estimates of $8.95 million. Avid Bioservices had a negative net margin of 46.62% and a negative return on equity of 57.49%. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What price target have analysts set for CDMO?
3 Wall Street analysts have issued 1-year target prices for Avid Bioservices' stock. Their predictions range from $4.00 to $10.00. On average, they expect Avid Bioservices' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Avid Bioservices.
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include Rocket Pharmaceuticals (RCKT), Abeona Therapeutics (ABEO), ANI Pharmaceuticals Inc Common Stock (ANIP), GlycoMimetics (GLYC), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA), CymaBay Therapeutics (CBAY), Arcus Biosciences (RCUS), Dova Pharmaceuticals (DOVA), Five Prime Therapeutics (FPRX), Rigel Pharmaceuticals (RIGL), Lannett (LCI), ChemoCentryx (CCXI), Geron (GERN) and Odonate Therapeutics (ODT).
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Mr. Paul J. Lytle, CFO & Principal Accounting Officer (Age 50)
- Mr. Mark R. Ziebell J.D., VP, Gen. Counsel & Corp. Sec. (Age 54)
- Dr. Shelley P. M. Fussey Ph.D., VP of Intellectual Property (Age 52)
- Ms. Tracy L. Kinjerski, VP of Bus. Operations
- Dr. Steven M. Chamow, Head of Technical Services (Age 64)
Has Avid Bioservices been receiving favorable news coverage?
News coverage about CDMO stock has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Avid Bioservices earned a daily sentiment score of 0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Avid Bioservices' major shareholders?
Avid Bioservices' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bandera Partners LLC (1.84%), BlackRock Inc. (1.37%), CVI Holdings LLC (1.07%), Schwartz Investment Counsel Inc. (0.86%), Wells Fargo & Company MN (0.40%) and Stifel Financial Corp (0.34%). View Institutional Ownership Trends for Avid Bioservices.
Which major investors are buying Avid Bioservices stock?
CDMO stock was bought by a variety of institutional investors in the last quarter, including Bandera Partners LLC, BlackRock Inc., CVI Holdings LLC, Schwartz Investment Counsel Inc., Wells Fargo & Company MN, Stifel Financial Corp, Millennium Management LLC and Northern Trust Corp. View Insider Buying and Selling for Avid Bioservices.
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $3.56.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $191.65 million and generates $57.63 million in revenue each year. The biopharmaceutical company earns $-28,150,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Avid Bioservices employs 323 workers across the globe.
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Avid Bioservices (NASDAQ:CDMO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Avid Bioservices in the last 12 months. Their average twelve-month price target is $7.00, suggesting that the stock has a possible upside of 96.63%. The high price target for CDMO is $10.00 and the low price target for CDMO is $4.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.00 | $7.00 | $10.00 | $10.00 |
| Price Target Upside: | 96.63% upside | 196.61% upside | 136.97% upside | 221.54% upside |
Avid Bioservices (NASDAQ:CDMO) Consensus Price Target History
Avid Bioservices (NASDAQ:CDMO) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Avid Bioservices (NASDAQ:CDMO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 3/7/2018 | | $0.6563 | | 3/16/2018 | 3/19/2018 | 4/2/2018 |
(Data available from 1/1/2013 forward)
Avid Bioservices (NASDAQ CDMO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.53%
Institutional Ownership Percentage: 19.00%
Avid Bioservices (NASDAQ CDMO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/15/2018 | Mark R Bamforth | Director | Buy | 50,000 | $2.25 | $112,500.00 | |  |
(Data available from 1/1/2013 forward)
Avid Bioservices (NASDAQ CDMO) News Headlines
| Source: |
|
Avid Bioservices (NASDAQ:CDMO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Avid Bioservices (NASDAQ:CDMO) Income Statement, Balance Sheet and Cash Flow Statement
Avid Bioservices (NASDAQ CDMO) Stock Chart for Thursday, May, 24, 2018
Loading chart…
